Verb similarity: comparing corpus and psycholinguistic data

Similarity, which plays a key role in fields like cognitive science, psycholinguistics and natural language processing, is a broad and multifaceted concept. In this work we analyse how two approaches that belong to different perspectives, the corpus view and the psycholinguistic view, articulate similarity between verb senses in Spanish. Specifically, we compare the similarity between verb senses based on their argument structure, which is captured through semantic roles, with their similarity defined by word associations. We address the question of whether verb argument structure, which reflects the expression of the events, and word associations, which are related to the speakers' organization of the mental lexicon, shape similarity between verbs in a congruent manner, a topic which has not been explored previously. While we find significant correlations between verb sense similarities obtained from these two approaches, our findings also highlight some discrepancies between them and the importance of the degree of abstraction of the corpus annotation and psycholinguistic representations.La similitud, que desempeña un papel clave en campos como la ciencia cognitiva, la psicolingüística y el procesamiento del lenguaje natural, es un concepto amplio y multifacético. En este trabajo analizamos cómo dos enfoques que pertenecen a diferentes perspectivas, la visión del corpus y la visión psicolingüística, articulan la semejanza entre los sentidos verbales en español. Específicamente, comparamos la similitud entre los sentidos verbales basados en su estructura argumental, que se capta a través de roles semánticos, con su similitud definida por las asociaciones de palabras. Abordamos la cuestión de si la estructura del argumento verbal, que refleja la expresión de los acontecimientos, y las asociaciones de palabras, que están relacionadas con la organización de los hablantes del léxico mental, forman similitud entre los verbos de una manera congruente, un tema que no ha sido explorado previamente. Mientras que encontramos correlaciones significativas entre las similitudes de los sentidos verbales obtenidas de estos dos enfoques, nuestros hallazgos también resaltan algunas discrepancias entre ellos y la importancia del grado de abstracción de la anotación del corpus y las representaciones psicolingüísticas.La similitud, que exerceix un paper clau en camps com la ciència cognitiva, la psicolingüística i el processament del llenguatge natural, és un concepte ampli i multifacètic. En aquest treball analitzem com dos enfocaments que pertanyen a diferents perspectives, la visió del corpus i la visió psicolingüística, articulen la semblança entre els sentits verbals en espanyol. Específicament, comparem la similitud entre els sentits verbals basats en la seva estructura argumental, que es capta a través de rols semàntics, amb la seva similitud definida per les associacions de paraules. Abordem la qüestió de si l'estructura de l'argument verbal, que reflecteix l'expressió dels esdeveniments, i les associacions de paraules, que estan relacionades amb l'organització dels parlants del lèxic mental, formen similitud entre els verbs d'una manera congruent, un tema que no ha estat explorat prèviament. Mentre que trobem correlacions significatives entre les similituds dels sentits verbals obtingudes d'aquests dos enfocaments, les nostres troballes també ressalten algunes discrepàncies entre ells i la importància del grau d'abstracció de l'anotació del corpus i les representacions psicolingüístiques

Verb similarity: Comparing corpus and psycholinguistic data

Similarity, which plays a key role in fields like cognitive science, psycholinguistics and natural language processing, is a broad and multifaceted concept. In this work we analyse how two approaches that belong to different perspectives, the corpus view and the psycholinguistic view, articulate similarity between verb senses in Spanish. Specifically, we compare the similarity between verb senses based on their argument structure, which is captured through semantic roles, with their similarity defined by word associations. We address the question of whether verb argument structure, which reflects the expression of the events, and word associations, which are related to the speakers' organization of the mental lexicon, shape similarity between verbs in a congruent manner, a topic which has not been explored previously. While we find significant correlations between verb sense similarities obtained from these two approaches, our findings also highlight some discrepancies between them and the importance of the degree of abstraction of the corpus annotation and psycholinguistic representations

Hacia una clasificación verbal automática para el español: estudio sobre la relevancia de los diferentes tipos y configuraciones de información sintáctico-semántica

En este trabajo nos centramos en la adquisición de clasificaciones verbales automáticas para el español. Para ello realizamos una serie de experimentos con 20 sentidos verbales del corpus Sensem. Empleamos diferentes tipos de atributos que abarcan información lingüística diversa y un método de clustering jerárquico aglomerativo para generar varias clasificaciones. Comparamos cada una de estas clasificaciones automáticas con un gold standard creado semi-automáticamente teniendo en cuenta construcciones lingüísticas propuestas desde la lingüística teórica. Esta comparación nos permite saber qué atributos son más adecuados para crear de forma automática una clasificación coherente con la teoría sobre construcciones y cuales son las similitudes y diferencias entre la clasificación verbal automática y la que se basa en la teoría sobre construcciones lingüísticas.Peer ReviewedPostprint (published version

Active implants in the middle ear pathology

[ES] Los implantes activos son útiles en el tratamiento de la hipoacusia neurosensorial, mixta con umbrales óseos superiores a 45 dB y algunas sorderas de transmisión. Constituyen una herramienta eficaz en pacientes que cumplen los criterios audiológicos y biológicos de cada uno de los sistemas. Proporcionan mejoras tonales y en la discriminación verbal similares a las audioprótesis externas, con mejor calidad del sonido. [EN] The active implants are useful in the treatment of sensorineural hearing loss, mixed deafness with bone thresholds above 45 dB and some transmission deafness. They are an effective tool for patients who meet the audiological and biological criteria. Provides tonal improvements and similar verbal discrimination external hearing aids with better sound quality

Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project

Introduction: Preoperative treatment and adequate surgery increase local control in rectal cancer. However, modalities and indications for neoadjuvant treatment may be controversial. Aim of this study was to assess the trends of preoperative treatment and outcomes in patients with rectal cancer included in the Rectal Cancer Registry of the Spanish Associations of Surgeons. Method: This is a STROBE-compliant retrospective analysis of a prospective database. All patients operated on with curative intention included in the Rectal Cancer Registry were included. Analyses were performed to compare the use of neoadjuvant/adjuvant treatment in three timeframes: I)2006–2009; II)2010–2013; III)2014–2017. Survival analyses were run for 3-year survival in timeframes I-II. Results: Out of 14, 391 patients, 8871 (61.6%) received neoadjuvant treatment. Long-course chemo/radiotherapy was the most used approach (79.9%), followed by short-course radiotherapy ± chemotherapy (7.6%). The use of neoadjuvant treatment for cancer of the upper third (15-11 cm) increased over time (31.5%vs 34.5%vs 38.6%, p = 0.0018). The complete regression rate slightly increased over time (15.6% vs 16% vs 18.5%; p = 0.0093); the proportion of patients with involved circumferential resection margins (CRM) went down from 8.2% to 7.3%and 5.5% (p = 0.0004). Neoadjuvant treatment significantly decreased positive CRM in lower third tumors (OR 0.71, 0.59–0.87, Cochrane-Mantel-Haenszel P = 0.0008). Most ypN0 patients also received adjuvant therapy. In MR-defined stage III patients, preoperative treatment was associated with significantly longer local-recurrence-free survival (p < 0.0001), and cancer-specific survival (p < 0.0001). The survival benefit was smaller in upper third cancers. Conclusion: There was an increasing trend and a potential overuse of neoadjuvant treatment in cancer of the upper rectum. Most ypN0 patients received postoperative treatment. Involvement of CRM in lower third tumors was reduced after neoadjuvant treatment. Stage III and MRcN + benefited the most

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362